舒尼替尼相关性血液学不良反应与晚期肾癌预后的相关性分析

王安邦; 潘秀武; 吕建敏; 刘溪; 吴震杰; 刘冰; 崔心刚; 曲乐; 王林辉

doi:10.13201/j.issn.1001-1420.2016.12.009

舒尼替尼相关性血液学不良反应与晚期肾癌预后的相关性分析

- 1 第二军医大学附属长征医院泌尿外科(上海, 200003);
- 2 第二军医大学附属第三医院泌尿外科;
- 3 南京大学医学院附属金陵医院泌尿外科

详细信息

通讯作者: 曲乐,E-mail:septsoul@hotmail.com; 王林辉,E-mail:wanglinhuicz@163.com

中图分类号: R737.14

收稿日期: 2016-04-18

Correlation between sunitinib-induced hematological toxicities and prognosis in advanced renal cancer patients

- 1 Department of Urology, Changzheng Hospital of Second Military Medical University, Shanghai, 200003, China;
- 2 Department of Urology, Third Affiliated Hospital of Second Military Medical University;
- 3 Department of Urology, Jinling Hospital of Nanjing University Medical School

More Information

Corresponding authors: QU Le ; WANG Linhui

Received Date: 18 April 2016

摘要

摘要: 目的:探讨舒尼替尼相关性血液学不良反应与晚期肾细胞癌的预后关系。方法:选取2010年6月~2014年6月上海长征医院泌尿外科收治的56例晚期肾癌患者,29例行肾脏原发病灶切除术,病理诊断为肾透明细胞癌。治疗方案:舒尼替尼50 mg,1次/d,采用4/2方案,即每治疗4周停2周为1个周期;每治疗1个周期或2个周期通过CT或MRI评价药物疗效。每周期血常规、肝肾功能检查评价不良反应。结果:中性粒细胞减少组,完全缓解(CR)2例(5.5%),部分缓解(PR)9例(25.0%),疾病稳定(SD)11例(30.6%),ORR为30.6%(8例);中性粒细胞正常组,CR 1例(5.0%),PR 2例(10.0%),SD 8例(40.0%),ORR为15.0%(3例)。中性粒细胞减少组患者的ORR高于中性粒细胞正常组患者的ORR,但差异无统计学意义。中性粒细胞减少组无进展生存期(12.2个月,95%CI: 10.8~13.6)较正常组(8.7个月,95%CI: 6.9~10.4)显著延长(P=0.007)。血小板下降组相较血小板正常组患者中位疾病无进展时间明显延长(P=0.011),中性粒细胞/淋巴细胞比率(＜2)较中性粒细胞/淋巴细胞比率(≥2)的患者中位疾病无进展时间明显延长(P=0.008)。结论:在舒尼替尼治疗中出现一些血液学不良反应的晚期肾细胞癌患者的中位无疾病进展时间更长,这些血液学不良反应可以作为预测药物疗效的有效指标。
- 舒尼替尼 /
- 晚期肾癌 /
- 中性粒细胞减少 /
- 血小板减少症 /
- 中性粒细胞/淋巴细胞
Abstract: Objective: To evaluate correlation between sunitinib-induced hematological toxicities and prognosis in patients with advanced renal cell carcinoma.Method: Fifty-six patients with advanced renal cell carcinoma were enrolled from June 2010 to June 2014, including 38 males and 18 females with median age 53.5 (range, 40-78) years old. Twenty-nine patients received prior radical nephrectomy and were diagnosed as renal clear cell carcinoma in pathology. Sunitinib was started at a dose of 50 mg/d orally on a four-week-on and two-week-off schedule. Treatment was given in six-week cycles until disease progression, lack of clinical benefit or unacceptable toxicity. CT or MRI scan were used to evaluate sunitinib efficacy every two cycles. Hematological toxicities were recorded regularly and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) based on absolute neutrophil and platelet counts every cycle.Result: Neutropenia group had complete response (CR) 2 (5.5%), partial response (PR) 9 (25.0%), stable disease (SD) 11 (30.6%) and objective response rate (ORR) 30.6%. Correspondingly, normal neutrophil group patients indicated CR 1 (5.0%), PR 2 (10.0%), SD 8 (40.0%)and ORR 15.0%. The ORR of neutropenia group patients was higher than that of normal neutrophil group, but there was no significant difference between two groups. Notably, neutropenia group was significantly associated with longer median progression-free survival (PFS) compared to normal neutrophil group (12.2 months, 95%CI: 10.8-13.6 vs. 8.7 months, 95%CI: 6.9-10.4, P=0.007). Besides, thrombocytopenia and ratio of neutrophil/lymphocytes (NLR＜2) were both correlated with longer median PFS compared to normal control group (P=0.011 and P=0.008, respectively).Conclusion: Sunitinib-induced hematological toxicities indicate longer median PFS in advanced renal cell carcinoma, which may be exploited as predictive factors for assessment of sunitinib efficacy.
- sunitinib /
- advanced renal cell carcinoma /
- neutropenia /
- thrombocytopenia /
- ratio of neutrophil/ lymphocytes

HTML全文

参考文献(18)

[1]	Motzer R J,Hutson T E,Tomczak P,et al.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J].N Engl J Med,2007,356(2):115-124.
[2]	Bhojani N,Jeldres C,Patard J J,et al.Toxicities associated with the administration of sorafenib,sunitinib,and temsirolimus and their management in patients with metastatic renal cell carcinoma[J].Eur Urol,2008,53(5):917-930.
[3]	Donskov F,Michaelson M D,Puzanov I,et al.Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinomapatients[J].Br J Cancer,2015,113(11):1571-1580.
[4]	Nagyiványi K,Budai B,BíróK,et al.Synergistic survival:a new phenomenon connected to adverse events of first-line sunitinib treatment in advanced renal cell carcinoma[J].Clin Genitourin Cancer,2016,14(4):314-322.
[5]	Fujita T,Wakatabe Y,Matsumoto K,et al.Leukopenia as a biomarker of sunitinib outcome in advanced renal cell carcinoma[J].Anticancer Res,2014,34(7):3781-3787.
[6]	Riesenbeck L,Bierer S,Hoffmeister I,et al.Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib[J].World J Urol,2011,29(6):807-813.
[7]	Motzer R J,Hutson T E,Tomczak P,et al.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2009,27(22):3584-3590.
[8]	Gore M E,Szczylik C,Porta C,et al.Safety and efficacy of sunitinib for metastatic renal-cell carcinoma:an expanded-access trial[J].Lancet Oncol,2009,10(8):757-763.
[9]	Gunduz S,Mutlu H,Uysal M,et al.Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors[J].Asian Pac J Cancer Prev,2013,15(8):3801-3804.
[10]	Pan X,Huang H,Huang Y,et al.Sunitinib dosing schedule 2/1improves tolerability,efficacy,and healthrelated quality of life in Chinese patients with metastatic renal cell carcinoma[J].Urol Oncol,2015,33(6):268.e9-15.
[11]	Taichman N S,Young S,Cruchley A,et al.Human neutrophils secrete vascular endothelial growth factor[J].J Leukoc Biol,1997,62(3):397-400.
[12]	Jensen H K,Donskov F,Marcussen N,et al.Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma[J].J Clin Oncol,2009,27(28):4709-4717.
[13]	Carus A,Gurney H,Gebski V,et al.Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients:Assessment of chemotherapy for resolution of unfavourable neutrophilia[J].J Transl Med,2013,11(1):189.
[14]	Dumitru C A,Lang S,Brandau S.Modulation of neutrophil granulocytes in the tumor microenvironment:mechanisms and consequences for tumor progression[C].Semin Cancer Biol,2013,23(3):141-148.
[15]	Donskov F.Immunomonitoring and prognostic relevance of neutrophils in clinical trials[J].Semin Cancer Biol,2013,23(3):200-207.
[16]	Ohno Y,Nakashima J,Ohori M,et al.Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma[J].J Urol,2010,184(3):873-878.
[17]	Unal D,Eroglu C,Kurtul N,et al.Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis[J].Asian Pac J Cancer Prev,2013,14(9):5237-5242.
[18]	Dirican A,Kucukzeybek Y,Erten C,et al.Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma:second line sunitinib treatment following IFN-alpha[J].Asian Pac J Cancer Pre,2013,14(3):2101-2105.